Table 4.
ATI Frequency Assayed by three Different Methods for all Studied Time Points.
| [IFX] μg/mL at W6 | bridging ELISA | IDKmonitor | ARIA | |
|---|---|---|---|---|
| W2 | IFX ≥4.4 n=44 | 0 | 0 | 0 |
| IFX <4.4 n=20 | 0 | 1 (5%) | 1 (5%) | |
| p | 1 | 0.33 | 0.33 | |
| W6 | IFX ≥4.4 n=44 | 0 | 1 (2.3%) | 2 (4.5%) |
| IFX <4.4 n=20 | 4 (20%) | 7 (35%) | 10 (50%) | |
| p | 0.007 | 0.002 | 0.001 | |
| W14 | IFX ≥4.4 n=44 | 2 (4.5%) | 7 (16%) | 12 (27.3%) |
| IFX <4.4 n=20 | 11 (55%) | 16 (80%) | 16 (80%) | |
| p | <0.0001 | <0.0001 | 0.0006 | |
| W22 | IFX ≥4.4 n=44 | 5 (11.4%) | 20 (45.5%) | 25 (56.8%) |
| IFX <4.4 n=20 | 15 (75%) | 18 (90%) | 18 (90%) | |
| p | <0.0001 | <0.0001 | 0.01 | |
| W54 | IFX ≥4.4 n=44 | 5 (11.4%) | 22(50%) | 27(61.3%) |
| IFX <4.4 n=20 | 15 (75%) | 18 (90%) | 18 (90%) | |
| p | <0.0001 | 0.002 | 0.02 |
ARIA, acid-dissociation radioimmunoassay (Sanquin, Amsterdam, The Netherlands); IDKmonitor, commercial kit (Immundiagnostik, Bensheim, Germany); IFX, infliximab; W, week.